Two members of FDA advisory committee resign after approval of controversial Alzheimer’s drug aducanumab

The two panel members resigned after FDA’s contentious decision to approve the drug, despite objections of its outside advisers, based not on the clinical data, but on the drug’s ability to reduce amyloid beta in the brain. It is believed drug will cost~ $56,000 / patient /year.

Source:

Biospace Inc.